Status:
COMPLETED
Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Schering-Plough
Conditions:
Hepatitis C
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.
Eligibility Criteria
Inclusion
- Hepatitis C patients (high titer, genotype1)
Exclusion
- Patients with autoimmune disorder
- Patients with negative HBs antigen
- Patients with hepatic cirrhosis, hepatic failure and hepatic cancer
- Patients with depression or psychoneurotic disorder
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00239252
Last Update
August 26 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Chubu Region, Japan
2
Chugoku Region, Japan
3
Kinki Region, Japan
4
Kyushu Region, Japan